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”Smoldering acute leukemia”, a variant of acute myelogenous leukemia, has been recognized
with frequent incidence in recent years. This is chracterized by benign clinical course, poor phys-
ical findings, leukopenia and mild anemia in the peripheral blood, and apparent infiltration of
abnormal myeloblasts in the bone marrow. Immunological studies of the host defence mechanism
were made, because the pathogenesis of its “smoldering” course has never been well understood.
Nine cases, seen during last 2 years, were investigated for immunological profile, especially the
cellular immunity. Purified protein derivative (PPD) skin test, i.e., tuberculin test, was found to
be positive in 8 of 9 cases (88.9%). Dinitrochlorobenzene (DNCB) sensitization test showed to
be positive in 4 of 6 cases examined (66.9%). Peripheral lymphocyte balstogenesis by stimulating
with phytohemagglutinin (PHA) was evaluated using the smear counting method. The blastoid
lymphocyte ratio was 55% at the median value (range: 31-68%), compared with 63% in normal
young control (age: 25-32) and 41% in normal aged control (age: 60-75). In this report, the cellu-
lar immunity in smoldering acute leukemia was proved to be preserved at the normal level and to
be more competent than that in aged group. The preserved cellular immunity is considered to ex-
plain the phenomenon of ”smoldering”, in other words, the exacerbating proliferation of leukemic
cells is suppressed by immuno-surveillance system.
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Abstract. "Smoldering acute leukemia", a variant of acute myelo-
genous leukemia, has been recognized with frequent incidence in
recent years. This is characterized by benign clinical course, poor
physical findings, leukopenia and mild anemia in the peripheral blood,
and apparent infiltration of abnormal myeloblasts in the bone marrow.
Immunological studies of the host defence mechanism were made, be-
cause the pathogenesis of its" smoldering to course has never been well
understood. Nine cases, seen during last 2 years, were investigated
for immunological profile, especially the cellular immunity. Purified
protein derivative (PPD) skin test, i.e., tuberculin test, was found to
be positive in 8 of 9 cases (88.9%). Dinitrochlorobenzene (DNCB) sen-
sitization test showed to be positive in 4 of 6 cases examined (66.9%).
Peripheral lymphocyte blastogenesis by stimulating with phytohemag-
glutinin (PHA) was evaluated using the smear counting method. The
blastoid lymphocyte ratio was 55% at the median value (range: 31-
68%), compared with 63% in normal young control (age: 25-32) and
41% in normal aged control (age: 60-75). In this report, the cellular
immunity in smoldering acute leukemia was proved to be preserved
at the normal level and to be more competent than that in aged group.
The preserved cellular immunity is considered to explain the pheno-
menon of "smoldering", in other words, the exacerbating prolifera-
tion of leukemic cells is suppressed by immuno.surveillance system.
"Smoldering acute leukemia" was designated first to be a variant of acute
myelogenous leukemia by Rheingold et al. in 1963 (1).
This type of leukemia has been recognized with frequent incidence in
recent years, in proportion to the increasing ratio of acute leukemia among
aged people (2) (3) (4).
The clinical pictures are characterized as follows: (i) A variant of acute
myelogenous leukemia, mostly seen among aged patients. (ii) Insidious onset
and prolonged course without specific chemotherapy. (iii) No life-threatening
acute infection and bleeding and no striking hepatosplenomegaly and lympha-
denopathy. (iv) Mild anemia and leukopenia with a few blasts in the peri-
pheral blood. And, (v) diagnostic bone marrow with infiltration of atypical
myeloblasts, "wild looking" and with prominent nucleoli (1) (3) (5).
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The bone marrow of smoldering acute leukemia may be hypocellular,
normocellular or hypercellular, and the number of blast cells may vary from
somewhere between 5 to 10 percent to almost complete infiltration. Most of
cases with hypoplastic leukemia may survive longer than the typical leukemia,
and by careful retrospective review, smoldering acute leukemia can be diag-
nosed (1) (3).
Although the clinical entity of smoldering acute leukemia can be differen-
tiated from typical acute leukemia, the pathogenesis of II smoldering" course
has never been well understood.
Recently there have been accumulated knowledges about the cellular im-
munity in malignant diseases, including cancers and malignant lymphomas.
And the cellular immunity for host defence mechanism has been found to play
an important role in malignant diseases. In typical acute leukemia, several
opinions concerning changes of immuno-competence which depends on the
severity of disease have been discussed by the study of delayed hypersensitivity
skin tests.
Because the immunological studies on smoldering acute leukemia has never
been reported previously, the following clinical investigations were made on 9
patients.
In this report, the analysis of the preserved competence of cellular im-
munity in smoldering acute leukemia was demonstrated by means of delayed
hypersensitivity skin tests and of the peripheral lymphocyte blastogenesis by
stimulating with phytohemagglutinin. And; the role of cellular immunity on
the host-tumor relationship in the condition of .1 smoldering" state was discussed.
MATERIALS AND METHODS
Patients: Nine patients had been encountered from September 1973 to Decem-
ber 1975; all cases were diagnosed as acute myelogenous leukemia. •. Smolder-
ing" acute leukemia was diagnosed retrospectively with the aids of criteria,
described before.
Heal thy controls consisted of the young group (age: 25-32) and the aged
group (age: 60 -75). Thirty patients with acute non-lymphocytic leukemia
(ANLL) (aged: 13-62), including acute myelogenous leukemia (AML), acute
promyelocytic leukemia (APL), monocytic leukemia (MoL), and erythroleuke-
mia (ErL), and 14 cases of acute lymphocytic leukemia (ALL) (age: 15-66) were
also chosen as controls.
Humoral immunological tests: Serological tests, including CRP, RA, ASLO,
Wasserman reaction, Australian antigen and Coombs' test, were done in routine
methods. Serum protein electrophoresis and immunoglobulin were examined
also in routine methods, described elsewhere.
Purified protein derivative (PPD) skin test, i.e. tuberculin test: PPD (intermediate
strength) used was a product of Nippon BCG Company. 0.1 ml was injected
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intradermally and the reactivity was measured after 48 hr. Then, this skin test
was judged as follows: (-): no reaction. (±): 5-9mm of erythema with in-
duration. (+): more than IOmm of erythema with induration. (+ +): more
than IOmm of induration with double erythema.
Dinitrochlorobenzene (DNCB) sensitization test: DNCB (Ishizu Pharmaceutical
Company) was dissolved with acetone. 0.1 ml of DNCB solution (2000 ,ug) was
sprayed topically on the shoulder, allowed to dry and covered with cotton
bandage for sensitization. Two weeks later, the challenge test was done on
the forearm with DNCB solutions of 2 different concentrations (5O,ug and
100 ,ug). Subsequently, this sensitization test was judged as follows. (6) (7):
(- ): no reaction. (+): erythema. (+ + ): erythema with induration. (+ + + ) :
erythema with induration and vesiculation.
Lymphocyte blastogenesis by stimulating with phytohemagglutinin (PHA): Venous
blood (3-l2ml) was drawn and lymphocytes were separated using a Lympho-
prep (Nyegaard and Co., Norway).
Collected lymphocytes were washed twice with the culture medium, RPMI
1640. 2 x 106 of lymphocytes were suspended in the culture medium, consisting
of 2ml RPMIl640 supplemented with 15% fetal calf serum. Phytohemagglu-
tinin-P (Difco Laboratories, U.S.A.), dissolved with RPMIl640, was added in
this culture tube at the final concentration of 5,ul per ml. This culture tube
was placed for 72 hr in an incubator with 5% CO2 atmosphere.
Then, the cultured lymphocytes were sedimented and collected to prepare
the smear on slide glasses. Smear was stained with May-Grunwald-Giemsa
solution. Blastoid lymphocytes were counted on 2 slide preparations by 2 hema-
tologists for objective observation. The criteria of b1astoid lymphocyte were
(i) increased cell size (12-20,um) and abnormal cell shape, (ii) increased nucleous
size with fine chromatin structure, (iii) a few apparent nucleoli, (iv) wide
basophilic cytoplasm, and (v) sometimes reticulum cell-like blastoid cells. The
average value in each was expressed as percentage for the ratio of lymphocyte
blastogenesis.
RESULTS
Smoldering acute leukemia belonged to .' myelogenous" type in all cases.
Males were more frequent than females (male: female = 7 : 2). Ages ranged
between 52 and 76, but 7 of 9 cases were more than 60 years old. (Table I)
In clinical findings, slight hepatomegaly was seen in 4 cases, one case had
high fever due to urinary tract infection and one had mild petechiae. In regard
to the clinical course, the longest duration of survival from the time of diagnosis
was 3 years and 9 months, and most of the cases survived one to 3 years with
supportive therapy by blood transfusion.
The peripheral blood showed 0 to 5% of myeloblasts with leukopenia com-
monly found. Case 2, who had 6400 of leukocyte count by the time of diag-
nosis, became leukopenic later during chronic course. In the bone marrow,
myeloblasts occupied 7.2 to 51.6%, and by careful observation the myeloblast
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was characterized by an atypical immature cell with prominent nucleoli. (Table
2)
TABLE 1 CASES OF SMOLDERING ACUTE LEUKEMIA: CLINICAL FINDINGS
ON ADMISSION
Case patient sex age type fever bleeding hepato- sp1eno- 1ymph-tendency mega1y mega1y adenopathy
1. T.Y. F 76 AML (+) (-) (- ) (-) (-)
2. Y.H. M 72 AML (- ) (-) (-) (- ) (-)
3. M.T. F 66 AML (-) (-) (-) (-) (-)
4. T.M. M 66 AML (-) (-) (+) (-) (-)
5. N.K. M 66 AML (- ) (-) (+) (-) (-)
6. K.M. M 64 AML (-) (+) (-) (-) (-)
7. M.M. M 52 AML (-) (- ) (+ ) (-) (-)
8. A.K. M 47 AML (-) (- ) (+ ) (- ) (-)
9. T.K. M 71 AML (- ) (-) (-) (-) (- )
TABLE 2 HEMATOLOGICAL DATA ON THE TIME OF DIAGNOSIS
Peripheral Blood Differ. Bone Marrow
---
case Hb. RBG Plat. Mye1o- NCC Mye1o- Promye1o- Eryth-
Img/d1) (x 104) WBC (x 104) blast (x 104) blast cyte raid(%) 1%) (%) (%)
1. 7.5 240 800 26.0 1 9.0 51.6 1.0 21.8
2. 8.5 225 6400 11.8 1 20.6 7.2 10.8 28.6
3. 5.0 174 2800 1.5 1 11.4 9.6 38.2
4. 5.0 163 1400 4.1 a 9.4 5.6 42.6
5. 3.7 110 1700 8.6 1 6.8 26.0 16.8 1.2
6. 7.7 210 2900 0.2 5 7.5 8.4 19.0 50.4
7. 6.2 205 600 1.2 3 0.3 8.8 8.4 38.8
8. 5.0 103 1900 0.9 2 7.3 43.2 4.8 18.0
9. 8.3 200 700 6.4 2 7.0 32.4 2.8 15.2
Serological tests revealed no particular tendency to any test. The positive
CRP was commonly seen in leukemia of acute phase. The electrophoretic
pattern of serum protein showed the increased amount of r-globulin fraction
with generally increased IgG level. No monoclonal gammopathy was observed.
(Table 3)
In cellular immunological profile, PPD test revealed the positive reactivity
in 8 cases out of 9 (88.9%). DNCB test was positive in 4 out of 6 cases with
erythema and induration. (Table 4)
Incidence of positive skin tests by PPD and DNCB in smoldering acute
leukemia was compared with ANLL and ALL. Positive reactivity of 88.9%
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by PPD test was significantly higher in comparison with 26.7% in ANLL and
35.7% in ALL. DNCB test showed the same tendency. (Table 5)
TABLE 3 EXAMINATIONS OF HUMORAL IMMUNOLOGICAL PROFILE
Serum r-globulin Immunoglobulin
Case CRP RA ASLO Wa-R Au-Ag Coombs Protein fraction (mg/d1)
(mg/d1) (%) IgG IgA IgM
1. (-) (-) 60 (-) (- ) (-) 7.3 27.8 1190 210 99
2. (1+) (-) 50 (-) (-) N.D. 6.9 23.3 3930 248 240
3. (2+) (-) 166 (-) (-) (-) 6.8 35.0 1780 210 132
4. (3+) (tt) 100 (-) (-) N.D. 7.4 20.0 1880 258 351
5. (2+) (-) 100 (-) (-) (-) 8.1 40.3 3530 225 132
6. (-) (-) 12 (-) N.D. (-) 6.8 22.5 1650 174 78
7. (4+) (-) N.D. (- ) N.D. N.D. 6.4 23.1 N.D.
8. (1+) (-) 12 (+) (-) (-) 6.1 17.1 N.D.
9. (1+) (-) 20 (-) (-) (-) 5. 7 20.1 N.D.
N. D.: Not done
TABLE 4 EXAMINATIONS OF CELLULAR IMMUNOLOGICAL PROFILE
Case PPD test DNCB test LymphocyteBlastogenesis (%)
1. (+) (-) 42
2. (-) N.D. 31
3. (+) (-) 68
4. (+) N.D. 42
5. (+) (tt ) 57
6. (tt ) (tt ) 65
7. (+) (tt ) 52
8. (+) (ttt ) 61
9. (+) N.D. N.D.
TABLE 5 INCIDENCE OF POSITIVE SKIN TESTS BY PPD AND DNCB IN
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The ratio of lymphocyte blastogeneisis ranged from 31 % to 68% with
median value of 55%. For the comparative evaluation, normal young and aged
groups showed 63% and 41 % in the median, respectively. (Fig. 1)













age: 52-76 (n=8) • I
Fig. 1. Lymphocyte Blastogenesis by PHA stimulation (Smear Counting Method) in
Smoldering Acute Leukemia, compared with Aged Group Control. (Ratio expressed in
percentage) 1m: median value)
DISCUSSION
In this paper, one aspect of immunological studies revealed the preserved
cellular immunity in the patients with smoldering acute leukemia for the first
time. The high incidence of positive reactivity by delayed hypersensitivity skin
tests and the normal range of lymphocyte blastogenesis were demonstrated.
The immunity of smoldering acute leukemia should be discussed in two
standpoints; one is the immunity of the aged people and the other is that of
patients with acute myelogenous leukemia. The importance of the immunolo-
gical tests in patients with malignant diseases was outlined with the special
reference to T-Iymphocyte function tests (8).
The relationship between the aging and the cellular immunity has been
reported by several researchers. According to Koide et al., the incidence of
positive PPD reactivity in aged group ranging 60 to 79 was 58.7% with the
control of 89.9% in younger group in Japanese population. Positive DNCB
sensitization reactivity was 63.6% in aged group (9).
The ability to develop the delayed hypersensitivity has been known to
become decreased according to aging.
According to Waldorf et al., 68% of the aged more than 70 years old
reacted to DNCB test in contrast to the normal responsiveness (94%) in 69 years
old or less (10).
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Nakayama et al. (11) demonstrated the tendency of decreasing ratio of
blastogenesis in the peripheral lymphocytes by PHA stimulation in proportion
to the aging. The significant correlation was apparently seen between the aging
and the decreasing blastogenesis ratio as well as the correlation in the reactivity
of delayed hypersensitivity.
These results suggest a close relationship of high incidence of malignancy
and autoimmune disease in the aged people, who might have the decreased
immuno-surveillance by T-lymphocyte function.
Immunological investigation on smoldering acute leukemia has never been
reported before, although there are many reports about the immunity of acute
leukemia, in relation to chemotherapy and immunotherapy. According to
Dupuy et al. by studing several kinds of skin tests, delayed hypersensitivity in
acute leukemia was shown to be slightly impaired before treatment and the
depressed delayed hypersensitivity during chemotherapy was correlated with
the severity of aplasia of the bone marrow (12). Hersh et al. emphasized that
patients with normal delayed hypersensitivity had better prognosis than those
with anergic reaction in the course of chemotherapy (13). Immunological study
in acute leukemia has been more advanced in investigating the tumor-associated
antigens, and the phenomenon of lymphocyte blastogenesis responding to the
stimulation of leukemic cells has been well known. Gutterman et ai. demon-
strated that a favorable prognosis was correlated with a vigorous response of
lymphocyte blastogenesis to autochthonous leukemic cells (14). Using BOG and
radiated leukemic cells, the immunotherapy for acute leukemia was aimed to
increase the host-defence immunity, by stimulating the immuno-surveillance
system of T-cell function in order to eradicate residual leukemic cells (15) (16).
In this study, several new findings about immunological profile in smol-
dering acute leukemia were revealed. (i) Patients preserved the competent
delayed hypersensitivity, in spite of old age, as high as young group. (ii) Peri-
pheral lymphocyte reacted almost normally to the stimulation of PHA, even
though peripheral blood was leukopenic and bone marrow was suppressed by
the infiltrating leukemic cells.
Because of technical difficulty, tumor-associated antigen in smoldering
acute leukemia has never been investigated yet. By T-cell function, however,
host-defence mechanism to eliminate leukemic cells, which may be recognized
as a not-self in antigenicity, is considered to explain the phenomenon of "smol-
dering"; in other words, clinical exacerbation due to proliferating leukemic
cells is suppressed by immuno-surveillance system, and the prolongation of
clinical course without any specific chemotherapy may be achieved, while
leukemic cells are confined in the bone marrow.
Several studies in regard to the pathogenesis of smoldering acute leukemia
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have been reported. Elevated muramidase levels and abnormal karyotypes by
chromosome analysis were revealed by Knospe et ai. (5). Kinoshita performed
the kinetic study of leukemic blasts in smoldering acute leukemia by labeling
cells with 3H-thymidine, found that the labeling index was lower than that of
the typical leukemia, and assumed that most of leukemic cells in smoldering
acute leukemia were "dormant" cells (17).
One of the cases studied here had the long duration of survival up to 3
years and 9 months after the diagnosis. During its course, three episodes of
pneumonia were considered retrospectively to contribute temporary improve-
ment in hematological findings, and the bacterial infection was presumed to
activate the non-specific immunity against leukemic cells in the host (18).
Recently clinical trial of neocarzinostatin, a new antitumor antibiotic, was
found to be effective to reduce the infiltration of leukemic cells in the bone
marrow in the cases of hypoplastic leukemia, including smoldering acute leu-
kemia, because neocarzinostatin was less suppressive to the bone marrow hema-
topoiesis than other conventional anti-leukemic agents.
In order to find out a clue of leukemogenesis and to develop an effective
treatment for acute leukemia, the enigmas concerning "smoldering" clinical
course should be solved through further studies using immunological methods.
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